Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of zero tariffs on pharmaceuticals exports from the UK to the US on South Suffolk constituency.

We have reached a landmark agreement with the United States of America, which means, unlike anywhere else in the world, life sciences companies exporting medicines from the United Kingdom to the US will face no tariffs to do so, protecting jobs and investment in the UK. This gives the UK a competitive advantage when selling to the global market, and the changes we’re making to increase what we spend on medicines will therefore help UK companies to export to the US, and shores up the investments global players have made in the UK, whilst also attracting further investments.

No assessment has been made of the potential impact of zero tariffs on pharmaceuticals exports from the UK to the US on the South Suffolk constituency.

No assessment has been made of the potential impact of zero tariffs being applied to pharmaceuticals exports from the UK into the US on National Health Service spending on medicines. The overall US agreement is expected to cost approximately £1 billion over the course of the Spending Review.